Scarica l'app Stockscreener
110.49
1.33%
-1.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
NEXTBio Capital Management LP Takes Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal (NASDAQ:PTGX) - Seeking Alpha
Keystone Investors PTE Ltd. Buys Shares of 26,390 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Shows Technical Strength and High Growth Momentum - ChartMill
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data - Benzinga
Protagonist Therapeutics director Waddill sells $969,120 in shares By Investing.com - Investing.com Canada
Protagonist Therapeutics director Waddill sells $969,120 in shares - Investing.com
Protagonist Therapeutics (NASDAQ: PTGX) director exercises 9,000 options, sells 9,000 shares under 10b5-1 plan - Stock Titan
PTGX Stock Quote Price and Forecast - CNN
571,825 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
Protagonist Therapeutics stock hits all-time high at 107.86 USD By Investing.com - Investing.com Nigeria
PTGX (NASDAQ) insider 10b5-1 sale of 9,000 shares; option exercise noted - Stock Titan
PTGX: Icotyde's strong launch and a robust pipeline drive growth, with Rusfertide approval expected soon - TradingView
Protagonist Therapeutics stock hits all-time high at 107.86 USD - Investing.com
Protagonist Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Clearbridge Investments LLC Buys Shares of 489,842 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Jumps 6.3% Amid Sector-Wide Rally - AlphaStreet
BNP Paribas Financial Markets Has $8.54 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Salinas Californian
Protagonist Therapeutics, Inc. - MLQ.ai
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Assessing Protagonist Therapeutics (PTGX) Valuation After Positive Rusfertide Data And Icotyde Approval News - Sahm
Avoiding Lag: Real-Time Signals in (PTGX) Movement - Stock Traders Daily
Geode Capital Management LLC Boosts Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Citizens raises Protagonist Therapeutics stock price target on platform validation - Investing.com
Protagonist Therapeutics Jumps 6.1% Amid Sector-Wide Rally - AlphaStreet
PTGX: Robust royalties, pipeline progress, and share buyback plans drive strong growth outlook - TradingView
Protagonist Therapeutics director Waddill sells $896,760 in common stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $896,760 in common stock - Investing.com
Director at Protagonist Therapeutics (PTGX) sells shares after exercising options - Stock Titan
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - ACCESS Newswire
Rusfertide results in polycythemia vera at European hematology congress - Stock Titan
Jefferies Financial Group Inc. Sells 816,503 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
[144] Protagonist Therapeutics, Inc SEC Filing - Stock Titan
Fisher Asset Management LLC Makes New Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Falls 1.76%; Stock Holds Above $95 Support Amid Biotech VolatilityGrowth ETF - The Legal Advocate
Protagonist Therapeutics to Present at Two Investment Bank Conferences in June 2026 - geneonline.com
Protagonist Therapeutics (PTGX) Stock Forecast & Analyst Ratings - Moomoo
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 - ACCESS Newswire
Protagonist CEO schedules two June healthcare conference talks - Stock Titan
PTGXProtagonist Therapeutics Inc Stock Price and Quote - Finviz
Discipline and Rules-Based Execution in PTGX Response - Stock Traders Daily
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Strong-Buy" at Wolfe Research - MarketBeat
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating - Investing.com India
Wolfe Research initiates Protagonist Therapeutics stock with outperform rating By Investing.com - Investing.com India
Eagle Health Investments LP Takes $5.01 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
6.83%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):